Implantica announces transition of Robert Frigg from board of directors to advisory board
Implantica AG (publ) today announces that Robert Frigg steps down from the board of directors and joins the advisory board in order to contribute to and support development projects.
“We would like to thank Robert for his invaluable contribution over the last 8 years as a member of the board of directors. He has provided much guidance over the many years, and we are very pleased to be able to continue to benefit from Robert’s extensive and broad product development expertise as a member of our advisory board,” said Peter Forsell, CEO of Implantica.
“It has been an honor to be part of the Implantica journey from such an early stage and a real thrill to have been a member of the board of directors during the company’s public listing on Nasdaq First North. I look forward to the opportunity to support Implantica in a more focused manner by contributing to and advising on the development of products going forward,” said Robert Frigg.
Robert Frigg joined the board of Implantica in 2013, and after his departure, Implantica will consist of five directors, who have significant experience leading public and private companies in the healthcare sector.
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, email@example.com
The information was sent for publication, through the agency of the contact person set out above, on July 23, 2021 at 16:00 CET.
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.